# Apnimed Inc. (APMD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $27.45, market value $1.1 billion.

## Valuation
- **P/E (trailing): 11.3×**. Apnimed Inc. trades at 11.3× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 29.7×**. Each dollar of revenue is priced at 29.7×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -6.8%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 8.9%**. The inverse of the P/E: 8.9% of the price is earned each year.

## Profitability
- **Gross margin: 82.6%**. Apnimed Inc. keeps 82.6% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -139.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -2.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: 0.3%**. 0.3% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 11.4%**. Return on all capital, debt included, is 11.4%.
- **Return on assets: -1.3%**. Each dollar of assets produces -1.3% of profit.

## Growth
- **Revenue growth (1 yr): 380.1%**. Revenue grew 380.1% over the last year.
- **EPS growth (1 yr): 99.2%**. Earnings per share rose 99.2%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: 0.0×**. It would take 0.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 0.41** (quick 0.41). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: -8.62**. A Z-score of -8.62 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Apnimed Inc. does not currently pay a dividend, but it returned -1.4% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (2 analysts). 2 analysts cover Apnimed Inc.; the consensus is strong_buy, with an average price target of $50.50 (+84% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -22.2%** (70.3% above the low). Trading 22% below its 52-week high.
- **RSI (14-day): 52**. An RSI of 52 is neutral.

Live score and charts: https://foliofundamentals.com/analyzer?s=APMD · Page: https://foliofundamentals.com/stocks/apmd

Not investment advice.